European Journal of Nuclear Medicine

, Volume 12, Issue 10, pp 510–514

99mTc-MAG3, a new renal imaging agent: Preliminary results in patients

  • Andrew TaylorJr.
  • Dennis Eshima
  • Naomi Alazraki
Article

DOI: 10.1007/BF00620476

Cite this article as:
Taylor, A., Eshima, D. & Alazraki, N. Eur J Nucl Med (1987) 12: 510. doi:10.1007/BF00620476

Abstract

99mTc-mercaptoacetyltriglycine (MAG3) is a new renal radiopharmaceutical which has been shown to have biological properties similar to131I-hippurate (OIH) in animals and volunteers.99mTc-MAG3 has now been compared with131I-orthoiodohippurate (OIH) in a group of patients with varying degrees of renal impairment. In all cases, the99mTc-MAG3 images were superior regardless of serum creatinine. Selected examples are illustrated including scans and renogram curves in a normal volunteer, transplant patients with creatinines of 9.8 mg/dl and 2.6 mg/dl respectively, and a furosemide study in a patient with questionable obstruction. Our preliminary results suggest that99mTc-MAG3 performs well in patients with impaired renal function and may well provide an acceptable replacement for OIH. A kit formulation has been developed and will soon be undergoing clinical evaluation.

Key words

MAG3Mercaptoacetyltriglycine99mTc-Renal radiopharmaceuticalsOIH131I-orthoiodohippurate

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • Andrew TaylorJr.
    • 1
  • Dennis Eshima
    • 1
  • Naomi Alazraki
    • 1
  1. 1.Division of Nuclear Medicine, Department of RadiologyEmory University HospitalAtlantaUSA